Say goodbye to plants: Synbio player Antheia earns new backers in quest to redesign flora-derived medicine manufacturing
The age of synthetic biology is officially upon us with super-unicorns like Ginkgo Bioworks changing the game in terms of how investors view those cell engineering platforms. Now, a California company looking to do away with fragile flora supply chains in drug development has earned a new round of investment to chase its goal.
Synbio player Antheia raised a $73 million Series B round it will use to advance its pipeline of compounds derived from a plant-alternative manufacturing process using whole yeast cell engineering, the company said Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.